

1 **Title:** IVUS Improves Outcomes with SUPERA Stents for the Treatment of Superficial Femoral-
2 popliteal Artery Disease

3 **Authors:** Prakash Krishnan (Prakash.Krishnan@mountsinai.org)^a, Raman Sharma
4 (Raman.Sharma@mountsinai.org)^a, Sriya Avadhani (Sriya.Avadhani@mountsinai.org)^a, Arthur
5 Tarricone (Arthur.Tarricone@mountsinai.org)^a, Allen Gee (Allen.gee97@gmail.com)^a, Serdar
6 Farhan (Serdar.Farhan@mountsinai.org)^a, Haroon Kamran (Haroon.Kamran@mountsinai.org)^a,
7 Annapoorna Kini (Annapoorna.Kini@mountsinai.org)^a, Samin Sharma
8 (Samin.Sharma@mountsinai.org)^a

9 **Affiliations**

10 a. Icahn School of Medicine at the Mount Sinai Hospital
11 The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R.
12 Kravis Cardiovascular Health Center, Department of Medicine/Cardiology, Icahn School of
13 Medicine at Mount Sinai, New York, NY

14 **Grant Support**

15 There was not grant support for this manuscript

16 **Correspondence**

17 Prakash Krishnan MD FACC
18 Phone Number: 212-241-6032
19 Fax Number: 212-348-7908
20 1 Gustave L. Levy Place Box 1030
21 New York, NY 10029
22 Prakash.Krishnan@mountsinai.org

23 **FINANCIAL DISCLOSURES**

24 All authors have no financial disclosures to make

25

26

27

28

29

30 **Abstract (210 words)**

31 Objectives: To determine the effect of intravenous ultrasound (IVUS) when used adjunctively
32 with nitinol interwoven bare metal stents in the management of femoropopliteal lesions.

33
34 Background: Nitinol interwoven bare metal stents represent an advancement in stent technology;
35 however nominal deployment remains an area of focus. Intravascular Ultrasound (IVUS) has
36 been shown to improve outcomes in both the coronary and peripheral vasculature by providing
37 the operator with greater vessel detail. The use of adjunctive IVUS with Nitinol bare metal
38 stents has not been widely studied.

39
40 Methods: This study included a cohort of 200 consecutive patients with peripheral artery disease.
41 All patients were treated with ≥ 1 Supera bare metal stent, and 91 received adjunctive IVUS
42 imaging prior to stent deployment. Deployment conditions of nominal, compressed, and
43 elongated were measured and the primary clinical outcomes included target lesion reintervention,
44 major and minor, below the knee amputation, and mortality.

45
46 Results: The patients who received IVUS had a significantly greater number of nominally
47 deployed stents ($p < 0.001$). Patients who had IVUS imaging also had significantly lower
48 reintervention rates compared to those who did not receive IVUS imaging ($p = 0.047$).

49
50 Conclusion: IVUS and angiography decreases clinically driven target lesion reintervention and
51 increases nominal deployment compared to angiography alone in femoropopliteal lesions treated
52 with interwoven bare metal nitinol stents.

53 **Keywords**

54 Intravenous Ultrasound, Supera, Stent, Peripheral Artery Disease

55

56 **Condensed Abstract (93 words)**

57 This retrospective study was done to examine the utility of intravenous ultrasound when used
58 adjunctively for visualization in the management of femoropopliteal lesions in peripheral artery
59 disease patients. There was total of 200 subjects and all were treated using the Supera nitinol
60 self-expanding stent. By the end of the study, the group of subjects treated with intravenous
61 ultrasound had significantly fewer reinterventions and had a greater rate of nominally deployed
62 stents. These findings suggest the beneficial role intravenous ultrasound has compared to
63 angiography alone in the management of femoropopliteal lesions with Supera stents.

64

65 **Abbreviations**

66 PAD = Peripheral Artery Disease

67 CD-TLR = Clinically Driven Target Lesion Reintervention

68 IVUS = Intravascular Ultrasound

69 PTA = Percutaneous Transluminal Angioplasty

70 DCB = Drug Coated Balloon

71

72

73

74

75

76 **Introduction**

77 Peripheral Artery Disease (PAD) affects over 200 million people globally with increasing
78 prevalence among the elderly (>80 years) population.(1) Endovascular management of PAD has
79 become the mainstay for treatment; however long term patency remains an area of focus.
80 Endovascular intervention success is multifactorial, with outcomes influenced by multiple
81 variables ranging from clinical presentation to appropriate interpretation of angiography.(2,3)
82 Stent malposition due to over or under sizing has been observed to result in increased clinically
83 driven target lesion reintervention (CD-TLR) and decrease in primary patency. Intravascular
84 Ultrasound (IVUS) has been shown to improve outcomes in both the coronary and peripheral
85 vasculature by providing the operator with greater vessel detail specifically assessment of plaque
86 buildup, measurement of lumen diameter, and possible assurance of proper stent deployment.(4)
87 In the peripheral vasculature, IVUS use has been observed to significantly improve primary and
88 secondary patency, freedom from any reintervention, freedom from any adverse limb event,
89 protective against vascular and non-vascular complications, and increase event-free survival
90 compared to angiography alone.(5-7)

91 The interwoven nitinol stent (Supera) represents an advancement in stenting technology
92 and has been shown to improve primary patency compared to bare metal stents, with rates
93 published as high as 90%.(8-11) Logical explanation of this improvement may be attributed to
94 the inherent helical structure of Supera, allowing greater resistance to compressive arterial forces
95 and resilience to stent fractures.(12) However, there has been variation in the success of studies,
96 with patency rates of Supera ranging from 55% -90%.(13,14) One factor that have been
97 speculated attributing to this variation is the mal-deployment of the Supera stents; and with fewer
98 nominally deployed stents, there will likely be greater target lesion revascularization.(15) While

99 nominal deployment is always the operator's objective, success of this has only been observed in
100 approximately 50% of treated subjects. The adjunctive use of IVUS with Supera stent technology
101 has not been widely studied and the objective of this analysis is to examine a cohort of
102 femoropopliteal PAD patients treated with Supera and IVUS vs Supera alone to observe
103 differences in both deployment condition as well as clinical outcomes.

104

105 **Methods**

106 Between March 2010 to March 2020, 200 consecutive patients were treated for
107 femoropopliteal PAD with Supera stents. All patients were adults (age ≥ 18 years), had a
108 confirmed clinical diagnosis of PAD, and were treated with at least one (≥ 1) Supera stent. All
109 patients were treated by guideline directed medical therapy. This study was approved by the
110 Institutional Review Board of the Icahn School of Medicine at the Mount Sinai Hospital:
111 Program of Protection of Human Subjects Committee.

112 The utility of adjunctive procedures and the duration of dual antiplatelet therapy was
113 under the discretion of the treating physician. Standard institutional practice of clopidogrel
114 (75mg/day), and aspirin (81mg) for 3 months were followed for post-procedure therapy.
115 Deployment conditions were assessed based on angiogram review and conditions were classified
116 as nominal, compressed, and elongated by two physicians independently. All disagreements were
117 resolved by the corresponding author

118 All angiograms were anonymized prior to review by the data collection team. Reference
119 vessel diameter was established through angiography or IVUS analysis when available. The
120 estimation of compression and elongation was determined by the operator, by dividing the
121 nominal stent length according to package insertion directions. Actual deployment length was

122 measured using a preprocedural attached measuring scale. Optical evaluation of the complete
123 stent was then conducted to examine for signs of elongation or compression. In keeping with the
124 findings in the SUPERB trial⁷, the authors defined the final three Supera stent dimensions as
125 elongation ($\geq 10\%$ of package insert length), compression ($\leq 10\%$ of package insert length), and
126 nominal ($-10\% \leq \text{Length} \leq +10\%$ of package insert length). 10% was chosen due to the increase
127 in CD-TLR observed in the SUPERB trial⁷ when the Supera deployment was either compressed
128 or elongated greater than 10%.

129 IVUS was performed using a system (Philips Healthcare) for all subsequent cases.
130 Images were acquired with a Volcano Eagle Eye(0.014-inch guidewire) or PV018 (0.018in guide
131 wire) solid-state phased array IVUS catheters. All the treating operators were experienced in the
132 use and interpretation of IVUS and IVUS was performed after pre-dilation and prior to stent
133 deployment. In cases with chronic total occlusion, pretreatment IVUS imaging was performed
134 after crossing of the occlusion. Manual pull back performed at a steady rate under fluoroscopic
135 imaging with bookmarking of frames at regular distances in relation to the radiopaque ruler for
136 all cases. In addition for all cases, the frame rate was set to maximum and gain and field of view
137 were optimized. Pullback acquisitions and saved still images were archived on softlink
138 international and saved for later analysis. IVUS diameter measurements were obtained at the
139 time of the procedure using the control module measurement software. IVUS diameters of the
140 proximal and distal Reference Vessel Diameter (RVD) were obtained at the most normal
141 appearing section immediately adjacent to the lesion. The IVUS diameter was measured in
142 millimeters and obtained following institutional guidelines by measuring the distance between
143 the intima-lumen boundaries in orthogonal planes and calculating the mean measurement. The
144 larger of the two measurements was used as the IVUS RVD. IVUS lesion length (mm) was

145 estimated by identifying the proximal and distal edge of the lesion according to IVUS while
146 under direct fluoroscopic control, and the distance between these points was measured using the
147 angiographic imaging length measurement technique described previously. Additional
148 information including the presence of post-angioplasty dissection was also obtained.

149 Associations were determined between Supera and the IVUS and non-IVUS groups, with
150 examination of the clinical outcome variables: re-intervention, mortality, and amputation. T-tests
151 or Chi-squares were used to compare continuous and categorical variables, respectively through
152 the utility of IBM SPSS Statistical viewer. Associations were presented as Odds Ratios (O.R),
153 Confidence Interval (C.I), p-value. A $p \leq 0.05$ was considered significant. All continuous
154 variables were presented as mean \pm standard deviation. Logistic regression models were also
155 conducted in SPSS, using the clinical outcomes: re-intervention, mortality, and amputation as
156 dependent variables and covariates as the variables that were considered significant in the
157 univariate analysis.

158

159 **Results**

160 A total of 236 SUPERA stents were used to treat 200 patients with lower limb
161 claudication or critical limb ischemia. Ninety one of these patients received IVUS imaging,
162 which was conducted in accordance with institution protocol. After angiographic review, all
163 cases were universally agreed upon. 164 limbs were treated with a single Supera stent, while 36
164 limbs were treated with >1 Supera stents. In the case of the 36 limbs treated with >1 Supera
165 stents, total stent length was used in order to determined compressed, nominal, or elongated.
166 Baseline and lesion characteristics were similar between both IVUS and non-IVUS treated
167 cohorts. Vessel diameter was observed to be significantly larger in the IVUS subgroup (5.13mm

168 vs 4.89mm, $p < 0.001$), lesion length (117.47mm vs 90.64mm $p < 0.001$), dissection (52.7% vs
169 22.0%, $p < 0.001$) and calcification was also observed to be more frequent in the IVUS subgroup
170 (Table 1 and 2).

171 All vessel preparation devices were utilized at the discretion of the operator and included
172 percutaneous transluminal angioplasty (PTA), drug coated balloons (DCB), atherectomies or
173 thrombectomy (Table 3). There were no significant differences in the adjunctive methods
174 between subgroups. There was a significant difference in the Supera stent size used within the
175 IVUS + angiography cohort compared to angiography alone, with more 5.5mm (36/91 (40%) vs
176 36/109 (33%) $p < 0.05$) and 6.0mm (33/91(36%) vs 15/109(14%), $p < 0.05$). IVUS utility was
177 associated with a lower CD-TLR: O.R = 0.482 [CI: 0.233,0.998] ($p = 0.047$). There was no
178 observed difference in lower extremity amputation between the two cohorts: O.R = 0.891
179 [CI:0.298, 2.670] ($p = 0.837$).

180 IVUS was also associated with stent deployment status. Nominal deployment was
181 achieved more frequently in the presence of IVUS utility: O.R = 2.674 [CI: 1.507,4.747],
182 $p < 0.001$), while elongated deployment was observed greater in the non-IVUS treated population
183 (OR = 3.523 [CI: 1.709, 7.267], $p < 0.001$) (Table 4). There was a greater rate of compressed
184 deployment in the non-IVUS subgroup, however this was not statistically significant.

185 The number needed to treat/number needed to harm (NNT/NNH), with the outcome of
186 re-intervention, showed that on average, 8.3 patients would have to be treated with over not
187 being treated with IVUS in order to have one additional patient not have an re-vascularization
188 event.

189

190 **Discussion**

191 Current findings of this study highlight the plausible benefit of adjunctive IVUS use with
192 Supera stent utilization. Significant differences were observed in angiography + IVUS compared
193 to angiography alone cohorts with regard to RVD (5.13mm vs 4.89mm , $p<0.5$), lesion
194 length(117.47 vs 90.64 , $p<0.5$), calcification (35 vs 14 , $p<0.001$), and dissection (48 vs 20 ,
195 $p<0.001$). Across the primary clinical outcomes, the group treated with IVUS-guidance and
196 Supera proceeded to show a significantly lower rate of re-intervention in comparison to the
197 Supera + angiography alone group at 12 months .

198 Across the board, IVUS has been well regarded for improving clinical outcomes within
199 coronary and iliac lesions, and continues to grow prominence in the scope of peripheral
200 intervention.(16-19) The addition of IVUS in peripheral vascular intervention, has been shown
201 to reduce short term and long term major adverse limb events (MALE) and decreased binary
202 restenosis in complete total occlusion (CTO).(20,21) A recent randomized controlled trial
203 comparing angiography + IVUS to angiography alone in femoropopliteal interventions reported
204 decreased binary restenosis when utilizing IVUS + angiography compared to angiography alone
205 at 12 months; and observed a high rate of disagreement in imaging findings including RVD and
206 lesion length, both of which were underestimated with angiography alone.(22) As endovascular
207 therapies evolve the importance of precise imaging becomes heightened. In the case of DCB
208 underestimating the RVD may result in poor apposition of DCB to vessel wall and ultimately
209 suboptimal drug delivery.(22) Mal-deployment of SUPERA has been suggested as plausible
210 explanation for the large variation of in CD-TLR across the literature with elongation carrying
211 the greatest risk of restenosis compared to nominal deployment.(15) The addition of IVUS has
212 been shown to affect medical decision making with regard to sizing of interventional device,
213 while the goal of our study was not to assess change in management as a result of IVUS use, the

214 authors did find significant differences in lesion characteristics including RVD, lesion length,
215 calcification and dissection.(22) In addition to these findings the Supera devices used in IVUS +
216 angiography arm were significantly larger than that of angiography alone arm and resulted in
217 significantly more nominal deployments than angiography alone (52.3% vs 38.5%, $p<0.001$).

218 While Supera on its own has historically been effective at treating infra-inguinal
219 superficial femoral artery lesions, the fact remains that sizing is a difficult variable to
220 control.(15,23) In our study, the use of IVUS likely attributed to improved vessel prep,
221 deployment, and ultimately more accurate sizing of Supera stent leading to the observed
222 reduction in CD-TLR. Consistent use of IVUS may improve accurate vessel measurements and
223 possibly reduce the error in stent deployment. These factors in combination could improve the
224 long term clinical outcomes of endovascular procedures.

225 Due to the retrospective design of this study, only associations could be determined from
226 the results. Another limitation was that mortality data was collected solely through EPIC records,
227 since social security numbers were often unavailable, preventing cross verification with national
228 death indexes. The present study also consists of a population from a heavily concentrated urban
229 location, making out findings less representative of all populations.

230

231 **Conclusion:**

232 IVUS and angiography decreases clinically driven target lesion reintervention and increases
233 nominal deployment compared to angiography alone in femoropopliteal lesions treated with
234 interwoven bare metal nitinol stents.

235

236 **Perspectives**

237 IVUS has been known to improve patency, protect from vascular adverse events, and reduce the
238 need for reintervention. This study explores IVUS as an adjunctive imaging method in the
239 management of femoropopliteal lesions with the Supera interwoven bare metal nitinol stents.
240 IVUS with angiography shows improved nominal deployment and reduced CD-TLR when
241 adjunctively used with Supera stents.

242

243 **References**

244

- 245 1. Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and
246 evidence-based facts. *Atherosclerosis* 2018;275:379-381.
- 247 2. Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent
248 expansion and neointimal proliferation of oversized Nitinol stents in peripheral
249 arteries. *Cardiovasc Intervent Radiol* 2009;32:720-6.
- 250 3. Richard R S. The Importance of Accurate Femoropopliteal Artery Sizing in
251 Endovascular Therapy. *Endovascular Today* 2012.
- 252 4. Fornell D. Understanding Intravascular Ultrasound (IVUS) Systems. *Diagnostic*
253 *and Interventional Cardiology* 2009.
- 254 5. Iida O, Takahara M, Soga Y et al. Efficacy of intravascular ultrasound in
255 femoropopliteal stenting for peripheral artery disease with TASC II class A to C
256 lesions. *J Endovasc Ther* 2014;21:485-92.
- 257 6. Panaich SS, Arora S, Patel N et al. Intravascular Ultrasound in Lower Extremity
258 Peripheral Vascular Interventions: Variation in Utilization and Impact on In-
259 Hospital Outcomes From the Nationwide Inpatient Sample (2006-2011). *J*
260 *Endovasc Ther* 2016;23:65-75.
- 261 7. Krishnan P, Tarricone A, Gee A et al. Analysis of Interwoven Nitinol Stenting for
262 the Treatment of Critical Limb Ischemia: Outcomes From an Average 3-Year
263 Follow-up Period. *Angiology* 2022;73:407-412.
- 264 8. Hiramoto JS, Teraa M, de Borst GJ, Conte MS. Interventions for lower extremity
265 peripheral artery disease. *Nat Rev Cardiol* 2018;15:332-350.
- 266 9. Meng FC, Chen PL, Lee CY, Shih CC, Chen IM. Real-World Comparison of Drug-
267 Eluting and Bare-Metal Stents in Superficial Femoral Artery Occlusive Disease
268 with Trans-Atlantic Intersociety Consensus B Lesions: A 2-Year, Single-Institute
269 Study. *Acta Cardiol Sin* 2018;34:130-136.
- 270 10. Ruiz CF, San Norberto García E, Domingos LF et al. supera Stent in Popliteal
271 Artery, 2 Years Follow-up Results. *European Journal of Vascular and*
272 *Endovascular Surgery* 2019;58:e455.

- 273 11. Werner M, Paetzold A, Banning-Eichenseer U et al. Treatment of complex
274 atherosclerotic femoropopliteal artery disease with a self-expanding interwoven
275 nitinol stent: midterm results from the Leipzig SUPERA 500 registry.
276 *EuroIntervention* 2014;10:861-8.
- 277 12. Garcia L, Jaff MR, Metzger C et al. Wire-Interwoven Nitinol Stent Outcome in the
278 Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the
279 SUPERB Trial. *Circ Cardiovasc Interv* 2015;8.
- 280 13. de Boer SW, van den Heuvel DAF, de Vries-Werson DAB et al. Short-term Results
281 of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With
282 Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and
283 Long Superficial Femoral Artery Lesions. *J Endovasc Ther* 2017;24:783-792.
- 284 14. San Norberto EM, Flota CM, Fidalgo-Domingos L, Taylor JH, Vaquero C. Real-
285 World Results of Supera Stent Implantation for Popliteal Artery Atherosclerotic
286 Lesions: 3-Year Outcome. *Ann Vasc Surg* 2020;62:397-405.
- 287 15. Garcia LA, Rosenfield KR, Metzger CD et al. SUPERB final 3-year outcomes using
288 interwoven nitinol biomimetic supera stent. *Catheterization and Cardiovascular
289 Interventions* 2017;89:1259-1267.
- 290 16. Buckley CJ, Arko FR, Lee S et al. Intravascular ultrasound scanning improves long-
291 term patency of iliac lesions treated with balloon angioplasty and primary
292 stenting. *J Vasc Surg* 2002;35:316-23.
- 293 17. Kim BK, Shin DH, Hong MK et al. Clinical Impact of Intravascular Ultrasound-
294 Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus
295 Biolimus-Eluting Stent Implantation: Randomized Study. *Circ Cardiovasc Interv*
296 2015;8:e002592.
- 297 18. Liu XM, Yang ZM, Liu XK et al. Intravascular ultrasound-guided drug-eluting stent
298 implantation for patients with unprotected left main coronary artery lesions: A
299 single-center randomized trial. *Anatol J Cardiol* 2019;21:83-90.
- 300 19. Tan Q, Wang Q, Liu D, Zhang S, Zhang Y, Li Y. Intravascular ultrasound-guided
301 unprotected left main coronary artery stenting in the elderly. *Saudi Med J*
302 2015;36:549-53.
- 303 20. Divakaran S, Parikh SA, Hawkins BM et al. Temporal Trends, Practice Variation,
304 and Associated Outcomes With IVUS Use During Peripheral Arterial Intervention.
305 *JACC Cardiovasc Interv* 2022;15:2080-2090.
- 306 21. Tsujimura T, Iida O, Takahara M et al. Clinical Impact of Intravascular
307 Ultrasound-Guided Fluoropolymer-Based Drug-Eluting Stent Implantation for
308 Femoropopliteal Lesions. *JACC: Cardiovascular Interventions* 2022;15:1569-1578.
- 309 22. Allan RB, Puckridge PJ, Spark JI, Delaney CL. The Impact of Intravascular
310 Ultrasound on Femoropopliteal Artery Endovascular Interventions: A
311 Randomized Controlled Trial. *JACC Cardiovasc Interv* 2022;15:536-546.
- 312 23. Palena LM, Diaz-Sandoval LJ, Sultato E et al. Feasibility and 1-Year outcomes of
313 subintimal revascularization with supera[®] stenting of long femoropopliteal
314 occlusions in critical limb ischemia: The "Supersub" Study. *Catheter Cardiovasc
315 Interv* 2017;89:910-920.
- 316

317 **Tables**

318 Table 1: Baseline

319 Table 2: Clinical Parameters

320 Table 3: Adjunctive Therapies

321 Table 4: Outcomes

Table 1: Baseline	IVUS (-) n=109	IVUS (+) n=91	p
Age	71.4 ± 10.6	72 ± 9.5	0.726
Gender			
Male	58 (53.2%)	44 (48.4%)	0.948
Female	51 (46.8%)	47 (51.6%)	0.948
Diabetes Mellitus	73(67.0%)	69 (75.8%)	0.170
Statin User	95 (87.1%)	82 (90.1%)	0.515
Smoker	87 (80.0%)	62 (68.1%)	0.059
Coronary Artery Disease	90 (82.6%)	68 (74.7%)	0.175
Critical Limb Ischemia	35 (32.1%)	28 (30.8%)	0.839
Hypertension	102 (93.6%)	89 (97.8%)	0.151
Hyperlipidemia	102 (93.6%)	86 (94.5%)	0.783
Rutherford			
1	0 (0.0%)	0 (0.0%)	N.A
2	3 (2.8%)	3 (3.3%)	0.822
3	71 (65.1%)	49 (53.8%)	0.105
4	34 (31.2%)	31 (34.1)	0.666
5	12 (11.0%)	7 (7.7%)	0.428
6	3 (2.8%)	1 (1.1%)	0.422

Table 2: Clinical Parameters	IVUS (-) n=109	IVUS (+) n=91	p
Reference Vessel Diameter			
(mm)	4.89 ± 0.79	5.13 ± 0.78	<0.001
4	43 (39.4%)	11 (12.1%)	<0.001
4.5	5 (4.6%)	0 (0.0%)	N.A
5	10 (9.2%)	11 (12.1%)	0.528
5.5	36 (33.0%)	36 (39.6%)	0.338
6	15 (13.8%)	33 (36.3%)	<0.001
Total Stent Length (mm)			
	98.44 ± 36.44	120.3 ± 25.38	0.042
40	8 (7.3%)	10 (11.0%)	0.372
60	22 (20.2%)	28 (30.8%)	0.087
80	23 (21.1%)	11 (12.1%)	0.095
100	11 (10.1%)	11 (12.1%)	0.653
120	20 (18.3%)	19 (20.9%)	0.653
150	25 (22.9%)	12 (13.2%)	0.083
Lesion Length (mm)			
	90.64 ± 41.7	117.47 ± 49.3	<0.001
Average Vessel Runoff			
	1.7 ± 1.0	1.7 ± 1.0	0.303
Vessel Runoff (#)			
0	12 (11.0%)	13 (14.3%)	0.485
1	33 (30.3%)	31 (34.1%)	0.567
2	32 (29.4%)	21 (23.1%)	0.316
3	29 (26.6%)	26 (28.6%)	0.757
Chronic Total Occlusion			
	46 (42.2%)	32 (35.2%)	0.310

Calcification	14 (12.8%)	35 (38.5%)	<0.001
Dissection	20 (22.0%)	48 (52.7%)	<0.001
Thrombus	5 (4.6%)	10 (11.0%)	0.087
Recoil	4 (3.7%)	1 (1.1%)	0.246
Perforation	2 (1.8%)	0 (0.0%)	0.194

Table 3: Adjunctive Therapies	IVUS (-) n=109	IVUS (+) n=91	p
DCB	48 (44.0%)	38 (41.8%)	0.746
PTA	61 (56.0%)	54 (59.3%)	0.630
Thrombectomy	3 (2.8%)	0 (0.0%)	0.910
Laser Atherectomy	1 (1.1%)	0 (0.0%)	0.951
Directional Atherectomy	86 (78.9%)	75 (82.4%)	0.532

Table 4: Outcomes	IVUS (-) n=109	IVUS (+) n=91	p
<hr/>			
Deployment			
Nominal	42 (38.5%)	57 (52.3%)	<0.001
Compressed	29 (26.6%)	22 (20.2%)	0.694
Elongated	38 (34.9%)	12 (11.0%)	<0.001
Amputation	8 (7.3%)	6 (6.6%)	0.837
Mortality	8 (7.3%)	4 (4.4%)	0.383
Re-intervention	28 (25.7%)	13 (14.3%)	0.047
<hr/>			